Skip to main content
MorphoSys AG logo

MorphoSys AG — Investor Relations & Filings

Ticker · MOR ISIN · DE000A3H2XW6 LEI · 529900493806K77LRE72 F Manufacturing
Open in API
Filings indexed 1,418 across all filing types
Latest filing 2003-01-09 M&A Activity
Country DE Germany
Listing F MOR

About MorphoSys AG

https://www.morphosys.com/

MorphoSys AG is a commercial-stage biopharmaceutical company focused on the discovery, development, and commercialization of innovative medicines, primarily for cancer patients. The company specializes in creating therapeutic monoclonal antibodies, utilizing its long-standing expertise and proprietary technology platforms to generate fully human antibodies. Its research and development efforts are concentrated on building a pipeline of novel treatments to address significant unmet medical needs in oncology. In February 2024, Novartis entered into an agreement to acquire MorphoSys, aiming to integrate its antibody technologies and oncology pipeline.

Recent filings

Filing Released Lang Actions
MorphoSys AG english
M&A Activity Classification · 99% confidence The document is a short corporate news announcement dated January 9, 2003, detailing a specific business transaction: Bayer exercising an option to license a therapeutic antibody program from MorphoSys AG. This announcement concerns a strategic partnership and potential future revenue streams (milestones and royalties) related to drug development. It is not a full financial report (10-K, IR), an earnings release (ER), a management discussion (MDA), or a proxy statement (DEF 14A). Since it details a significant business development, potential financing/licensing activity, and is presented as a general corporate news item, it fits best under 'Regulatory Filings' (RNS) as a general corporate announcement that doesn't fit the more specific business transaction codes like M&A (TAR) or Capital Change (CAP). Given the nature of the announcement (licensing/collaboration update), RNS is the most appropriate fallback for a non-standard corporate event disclosure.
2003-01-09 English
MorphoSys AG english
Legal Proceedings Report Classification · 99% confidence The document text explicitly discusses a legal matter: 'MorphoSys Confirms Positive Recommendation in Lawsuit Against Applied Molecular Evolution'. It details the filing of a complaint, allegations of patent infringement, counterclaims, and a 'Report and Recommendation' from a Magistrate Judge regarding summary judgment motions. This content directly relates to significant lawsuits and legal proceedings involving the company. Therefore, the appropriate classification is Legal Proceedings Report (LTR). The document length (2054 chars) is substantial enough to be the report/update itself, not just an announcement of a report.
2003-01-08 English
MorphoSys AG english
Legal Proceedings Report Classification · 95% confidence The document is labeled as an 'Ad-hoc' announcement dated December 23, 2002. It details the settlement of patent disputes between MorphoSys AG and Cambridge Antibody Technology (CAT), including financial terms (annual payments, equity stake) and licensing agreements. This type of announcement, concerning a significant legal/business event that is not a standard periodic financial report (like 10-K or IR) or a management change, fits best under the general category for regulatory announcements that don't have a more specific code. Since it is a specific, non-standard regulatory disclosure, and not a presentation (IP), a dividend notice (DIV), or a director dealing report (DIRS), the most appropriate fallback is 'Regulatory Filings' (RNS). It is too detailed to be a simple Report Publication Announcement (RPA) which usually just announces the release of another document.
2002-12-23 English
MorphoSys AG english
Regulatory Filings Classification · 98% confidence The document is a short corporate news announcement dated November 11, 2002, detailing a milestone achievement and payment received from Centocor regarding the installation of the AutoCAL system. It is not a comprehensive financial report (like 10-K or IR), nor is it a transcript, director dealing report, or dividend notice. It is a general corporate update about a collaboration milestone. Since it is a specific corporate news announcement that doesn't fit the highly specific categories like ER, DIV, or DIRS, and it is not merely announcing the publication of a larger report (RPA), the most appropriate general category is Regulatory Filings (RNS), which serves as the fallback for miscellaneous corporate news announcements not covered elsewhere.
2002-11-11 English
MorphoSys AG english
Earnings Release Classification · 100% confidence The document explicitly states it is an 'Ad-hoc' announcement reporting 'financial results for its third quarter and nine months ended September 30, 2002.' It provides key financial figures (revenues, expenses, net loss, cash balance) and also announces strategic changes (restructuring measures). This content aligns perfectly with an Earnings Release (ER), which is the initial announcement of periodical financial results, often accompanied by brief strategic commentary. It is too brief and focused on highlights to be a full Interim Report (IR) or Annual Report (10-K). 9M 2002
2002-11-05 English
MorphoSys AG correction
Share Issue/Capital Change Classification · 99% confidence The document is an 'Ad-hoc' announcement dated October 28, 2002, detailing a correction to a previous announcement regarding the issuance of shares to XOMA as part of a license agreement. The core subject is the resolution by the Management Board to issue shares following a capital increase against contribution in kind. This action directly relates to changes in the company's capital structure and financing activities. Based on the definitions, 'Capital/Financing Update' (CAP) is the most appropriate category for announcements concerning share issuance, capital increases, and financing transactions, even when structured as a correction to an earlier filing.
2002-10-28 English

Browse filings by year

22 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.